All News
DSB - Safety Update and Drug Shortages January 2017
RheumNow will periodically report safety issues as Drug Safety Bulletins. These will update you with safety issues, label changes and reports of new, ongoing and resolved drug shortages that affect rheumatology. If you have suggestions or information about specific drug shortages or drug safety issues, please email us at info@rheumnow.com.
Read ArticleC5a and Neutrophils as Early Mediators in Inflammatory Arthritis
Researchers from the Massachusetts General Hospital (MGH) have studied the initial steps in an animal model of inflammatory arthritis and found that complement C5a is critical to neutrophils migration into joints.
Read ArticleTies to Pharma Influences Clinical Trial Results
A study published in The BMJ shows that financial ties between researchers and companies that make the drugs they are studying are independently associated with positive trial results; thereby questioning the bias in these objective trials.
Read ArticleFDA Issues Draft Guidance on Biosimilar Interchangeability
Interchangeability, or the substitution of a biosimilar for its innovator biologic, is on the horizon. Will the prescriber chose the biosimilar in place of the originator? Or will this allow pharmacists or healthcare plans to substitute a biosimilar, without intervention from a healthcare provider?
Read ArticleThe RheumNow Week in Review – 20 January 2017
Dr. Jack Cush reviews highlights from the past week on RheumNow.
Read ArticleWho Is At Risk to Lose Insurance if the ACA is Changed or Repealed?
If Congress changes or repeals the Affordable Care Act (ACA), which adults are at risk of losing health insurance?
Read ArticleEULAR Revised Recommendations for Fibromyalgia
The European League Against Rheumatism (EULAR) recommendations for fibromyalgia (FM) management were published in 2007 and largely had recommendations based on expert opinion’. These guidelines were updated in May of 2015 after a systematic reviews and meta-analyses of the data.
Read ArticleConsensus Guidelines for Juvenile Dermatomyositis Management
SHARE (Single Hub and Access point for pediatric Rheumatology in Europe) was established in 2012 to optimise the diagnosis and treatment of several pediatric diseases. They have recently published their recommendations regarding the diagnosis and management of juvenile dermatomyositis (JDM).
Read ArticleDietary Intake Triggers Inflammation
IL-1β, along with pancreatic insulin, helps regulate blood sugar levels, as well as chronic inflammation.
Read ArticlePatient and Provider Education Fails to Improve Osteoarthritis Outcomes
A randomized trial of 537 knee osteoarthritis (OA) patients in the Duke Healthcare system has shown that patient- and provider interventions were no better than the usual standard of care.
Read ArticleRituximab Effects on ANCA, IgG and Infectious Risk in ANCA-Associated Vasculitis
Rituximab has significantly changed the management of patiehts with ANCA-associated vasculitis (AAV). Yet the longitudinal assessment of such patients needs to be guideded by clinical and laboratory parameters.
Read ArticlePPIs Reduce Post-Hip Fracture Mortality
The association between the use of proton pump inhibitors (PPIs), osteoporosis (OP) and OP-related fragility fractures has been a topic of ongoing discussion in rheumatology community.
Read ArticleThe RheumNow Week in Review – 13 January 2017
Dr. Jack Cush reviews highlights from this past week on RheumNow.com:
Read ArticlePsoriatic Arthritis Patients have More Heart Disease
A study of 90 consecutive male (50.3±11.1 years) with psoriatic arthritis (PsA) were were compared to 240 age matched controls without known cardiovascular (CV) diseases who underwent angiography for chest pain and/or multiple CV risk factors.
Read ArticleStatins Don't Increase Risk of Colchicine Myopathy
Neuromyopathy is a rare side effect of chronic colchicine use. Statins are more commonly implicated as a cause of drug-induced myopathy.
Given the frequent occurrence of the metabolic syndrome, simultaneous use of both colchicine and statins is common.
Read ArticleTREG Innovators Win the Crafoord Prize
The 2017 Crafoord Prize from the Royal Swedish Academy of Sciences has been awarded to a Japanese scientists and two American scientists for their discovery and research on T regulatory cells (TRegs).
Read ArticleMultiple Comorbidity Risks with Giant Cell Arteritis
Elderly patients treated with high doses of corticosteroids are bound to have multiple medical problems. But this was only recently quantified by researchers analyzing a a population-based cohort of biopsy-proven giant cell arteritis (GCA) patients in Southern Sweden.
Read ArticleLess Education Yields Higher Cardiovascular Risk
Similar to the findings in rheumatoid arthritis, lower levels of education can have predictable negative consequences. And the reasons for more heart attacks with lower educational levels is not entirely clear.
Read ArticleDo Exercise ‘Weekend Warriors’ Lower Their Risk of Death?
Is being a “weekend warrior” and cramming the recommended amount of weekly physical activity into one or two sessions associated with lower risks for death?
A new article published online by JAMA Internal Medicine suggests that compared with inactive adults, weekend warriors who performed the recommended amount of 150 minutes of moderate or 75 minutes of vigorous activity in one or two sessions per week had lower risks for death from all causes, cardiovascular disease (CVD) and cancer.
Weight Loss Improves Psoriasis
Jennsen et al previously reported their findings regarding weight reductions ability to improve cutaneous psoriasis at the European Academy of Dermatology and Venereology (EADV) meeting in 2015, Now their results are published in The American Journal of Clinical Nutrition.
Read Article